Tooth Agenesis Association with Self-reported Family History of Cancer

2012 ◽  
Vol 92 (2) ◽  
pp. 149-155 ◽  
Author(s):  
E.C. Küchler ◽  
A. Lips ◽  
P.N. Tannure ◽  
B. Ho ◽  
M.C. Costa ◽  
...  

It has been proposed that tooth agenesis and cancer development share common molecular pathways. We performed a cross-sectional study to investigate the epidemiological and molecular association between tooth agenesis and self-reported family history of cancer. Eighty-two individuals with tooth agenesis and 328 individuals with no birth defect were recruited from the same institution. Tooth agenesis was assessed in permanent teeth and was defined based on the age of the participants and when initial tooth formation should be radiographically visible. We also investigated the role of genes involved in dental development that have been implicated in tumorigenesis, and 14 markers in AXIN2, FGF3, FGF10, and FGFR2 were genotyped. Individuals with tooth agenesis had an increased risk of having a family history of cancer ( p = 0.00006; OR = 2.7; 95% C.I., 1.6-4.4). There were associations between AXIN2, FGF3, FGF10, and FGFR2 with tooth agenesis [ i.e., individuals who carried the polymorphic allele of FGFR2 (rs1219648) presented higher risk for having premolar agenesis ( p = 0.02; OR = 1.8; 95% C.I., 1.1-3.0)]. In conclusion, tooth agenesis was associated with positive self-reported family history of cancer and with variants in AXIN2, FGF3, FGF10, and FGFR2. Prospective studies are needed to confirm if tooth agenesis can be used as a risk marker for cancer.

2018 ◽  
Vol 2 (3) ◽  
Author(s):  
Julie Abildgaard ◽  
Magnus Glindvad Ahlström ◽  
Gedske Daugaard ◽  
Dorte Lisbet Nielsen ◽  
Anette Tønnes Pedersen ◽  
...  

Abstract Background Current international guidelines recommend systemic hormone therapy (HT) to oophorectomized women until the age of natural menopause. Despite an inherited predisposition to estrogen-dependent malignancies, the guidelines also apply to women oophorectomized because of a family history of cancer. The objective of this study was to investigate the impact of HT on mortality and risk of cancer in women oophorectomized because of a family history of cancer. Methods A nationwide, population-based cohort was used to study women oophorectomized because of a family history of cancer (n = 2002). Comparison cohorts included women from the background population individually matched on age (n = 18 018). Oophorectomized women were subdivided into three groups: oophorectomized at 1) age 45 years or younger not using HT, 2) age 45 years or younger using HT, 3) older than age 45 years, and their respective population comparison cohorts. Results Women oophorectomized at age 45 years or younger using HT had increased overall mortality (mortality rate ratio [MRR] = 3.45, 95% confidence interval [CI] = 1.53 to 7.79), mortality because of cancer (MRR = 5.67, 95% CI = 1.86 to 17.34), and risk of overall cancer (incidence rate ratio [IRR] = 3.68, 95% CI = 1.93 − 6.98), primarily reflected in an increased risk of breast cancer (IRR = 4.88, 95% CI = 2.19 − 10.68). Women oophorectomized at age 45 years or younger not using HT and women oophorectomized at older than age 45 years did not have increased mortality, mortality because of cancer, or risk of overall cancer, but they had increased risk of breast cancer (IRR = 2.64, 95% CI = 1.14 to 6.13, and IRR = 1.72, 95% CI = 1.14 to 2.59, respectively). Conclusions Use of HT in women oophorectomized at age 45 years or younger with a family history of cancer is associated with increased mortality and risk of overall cancer and breast cancer. Our study warrants further investigation to establish the impact of HT on mortality and cancer risk in oophorectomized women with a family history of cancer.


2009 ◽  
Vol 13 (4) ◽  
pp. 461-465 ◽  
Author(s):  
Yue Chen ◽  
Donna C Rennie ◽  
James A Dosman

AbstractObjectiveTo examine the joint effect of family history and BMI on diabetes.DesignCross-sectional study.SettingA rural community in Saskatchewan, Canada.SubjectsThe analysis was based on data from 2081 adults, 18–79 years of age, who participated in the Humboldt Study conducted in 2003. Doctor-diagnosed diabetes and family history of diabetes of biological parents and siblings were self-reported. Body weight and height were objectively measured. The interaction of family history and BMI on diabetes was assessed on an additive scale.ResultsThe prevalence of diabetes was 7·9 %, and BMI and history of diabetes were two important predictors. The adjusted prevalence ratios were 1·76 (95 % CI 1·37, 2·27) and 2·59 (95 % CI 2·05, 3·31) for those with a BMI of 25·0–29·9 kg/m2 and of at least 30 kg/m2, respectively, compared with a BMI of less than 25 kg/m2, and was 2·41 (95 % CI 2·08, 2·80) for those with a family history of diabetes v. those without. The data indicated an additive interaction of family history and BMI on diabetes.ConclusionsWhen exposed to both family history and overweight/obesity, individuals would have an increased risk that was greater than the sum of their single effects. Reduction of BMI would also reduce the risk of diabetes associated family history.


2021 ◽  
Vol 25 (3) ◽  
pp. 221-231
Author(s):  
Andrada Ciucă ◽  
Ramona Moldovan ◽  
Sebastian Pintea ◽  
Adriana Băban

Purpose: Understanding the factors impacting individuals’ emotional distress in the context of a family history of cancer is key in designing and implementing psychosocial interventions. Our study investigated the extent to which having a family history of cancer is associated with emotional distress and whether the perceived risk to develop colorectal cancer (CRC) plays any role in this equation. Methods: This cross-sectional study included 253 individuals from the general population who volunteered to take part in this study. We assessed their family history of cancer and perceived risk for developing CRC, and assessed the emotional distress. Findings: Individuals with a family history of cancer have higher levels of emotional distress compared to individuals without a family history, t(251)=-10.16, p<.001. Our data show that risk perception to develop CRC moderates the relationship between the family history of cancer and emotional distress (β=0.38, CI=(1.68, 5.92), r2=0.24, p<.001, d=0.25). Conclusion: This study was aimed at corroborating the role family history of cancer and risk perception have in explaining the emotional distress associated with cancer. Our results contribute to a clearer understanding of the impact family history of cancer has on emotional distress and show that risk perception is key in this relationship.


2021 ◽  
pp. 1-7
Author(s):  
Mohamad A. Kalot ◽  
Philipp Dahm ◽  
Lindsay G. Cowell ◽  
Lama Noureddine ◽  
Reem A. Mustafa

<b><i>Purpose:</i></b> Renal cysts are a frequent incidental finding on cross-sectional radiographic imaging. While most cysts are indolent, individuals with such cysts are frequently monitored for interval growth and potential malignant transformation, which is ultimately rare. In this study, we aimed to assess patients’ values and preferences (believes and attitudes) about renal cysts. <b><i>Methods:</i></b> We deployed a cross-sectional survey to a random sample of patients with a diagnosis of renal cysts who were identified by billing code and self-identification. We collected data about demographics, insurance status, family history and overall health, and characteristics of patients with renal cysts. We performed a binary regression analysis (adjusted for age, gender, family history of cancer and kidney disease, and treatment plan for renal cysts) to determine anxiety predictors in patients with renal cysts. <b><i>Results:</i></b> We included 301 respondents in whom billing code and self-identification corresponded; of these, 138 had renal cysts and 163 did not. In an adjusted regression analysis, there was a suggestion that a clear management plan (OR = 0.49, 95% CI [0.22–1.11]) (<i>p</i> value 0.08) may be associated with less anxiety and a family history of renal disease may be associated with more anxiety (OR = 1.94 [0.76–4.94]) (<i>p</i> value 0.17). Family history of cancer also did not significantly predict anxiety (OR = 0.54 [0.24–1.19]) (<i>p</i> value 0.13). All these results were not statistically significant and had wide confidence intervals of the effect estimates make the results imprecise. <b><i>Conclusion:</i></b> Findings of this pilot study suggest a clear management plan for the renal cyst(s) management may be associated with a lower level of anxiety, thereby by emphasizing the importance of good communication, patient engagement and evidence-based guidance. More definitive, adequately powered studies are needed to evaluate this finding further. In addition, further studies exploring differences in imaging practices, patient symptomatology and patient engagement by different provider types would be insightful. Ultimately, tools to improve shared decision-making are needed to provide more patient-centered care.


Pain Medicine ◽  
2019 ◽  
Vol 20 (10) ◽  
pp. 2043-2050
Author(s):  
Selen Gur-Ozmen ◽  
Ruhan Karahan-Ozcan

AbstractObjectiveStudies have shown a relationship between insulin resistance (IR) and migraine that is more evident in some migraineurs. Long-term use of various drugs and increased risk of diverse side effects is an unavoidable reality in this population of patients. Thus, in this study, we aimed to investigate factors associated with IR in migraine and the impact of chronic usage of various drugs, which might play a part in development of IR.DesignCross-sectional study.SettingGebze Fatih General Hospital, Kocaeli, Turkey.SubjectsMigraine patients (N = 150) were investigated.MethodsWeight, height, waist circumference, and blood pressure were measured. Fasting glucose, fasting insulin, glycated hemoglobin, and lipid profile were also measured. IR was selected as a dependent variable. The independent variables included age, cigarette smoking, alcohol consumption, family history of migraine, diabetes mellitus and hypertension, characteristics of pain, migraine triggers and subgroups, medication used during attack treatment, medication used as prophylactic treatment, and oral contraceptive treatment. Descriptive analysis and multivariate logistic regression were performed.ResultsCentral obesity (odds ratio [OR] = 7.131, 95% confidence interval [CI] = 2.451–20.741, P < 0.0001), metoclopramide treatment during an attack (OR = 3.645, 95% CI = 0.996–13.346, P = 0.041), family history of DM (OR = 3.109, 95% CI = 1.189–8.132, P = 0.035), nonsteroidal anti-inflammatory drug (NSAID) usage during an attack (OR = 2.578, 95% CI = 1.053–6.311, P = 0.043), and negative family history of hypertension (OR = 0.226, 95% CI = 0.085–0.602, P = 0.002) were significant factors for exhibiting IR in migraine.ConclusionsOur study demonstrates an association between metoclopramide and NSAID treatments and IR in migraine.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 1777-1777
Author(s):  
Eva Domingo-Domènech ◽  
Yolanda Benavente ◽  
Carlos Montalbán ◽  
Ramon Bosch ◽  
Josep Gumà ◽  
...  

Abstract Background and aims: Family history of cancer in lymphoma patients has largely been described. On the other hand, genetic susceptibility associated to lymphoma risk is being investigated at the present time. However, single nucleotide polymorphisms (SNPs) associated to the entity among those reporting family history of cancer have yet not been identified. In a previous study of our group, we identified that the probability of having a first-degree relative with cancer was significantly higher among the patients with lymphoid neoplasm than among the control subjects (43% vs 35%, p&lt;0.05). When analysing by lymphoma subtypes, B-cell lymphoma, chronic lymphocytic leukaemia (CLL) and multiple myeloma (MM) patients were significantly more likely to report a first-degree relative with any cancer, with a risk increase ranging from 1.4 up to 2.1 among CLL patients. Thus, a 2-to 4-fold increased risk of lymphoma has been identified in patients with a family history of hematologic disease or lymphoma in first-degree relatives, with CLL, MM and Hodgkin’s lymphoma (HL) being the three entities more consistently reported. The purpose of this study was to evaluate the role of genetic variants of several polymorphisms in the risk of developing a lymphoid neoplasm among subjects with family history of cancer in the case-control study Epilymph. Material and methods: Newly diagnosed cases of lymphoma were recruited between 1998–2002 in 4 Spanish centers. Controls were hospitalized patients matched to the cases by age, gender and study center. Personal interviews were conducted in order to collect data on demographics, environmental exposure, medical and family history, including cancer. The site of cancer, age at diagnosis, and status of any affected relatives with cancer were requested. In this analysis, we only included those subjects who reported a family history of cancer. 72 SNPs in 47 genes were included in the analysis. DNA of 503 cases and 569 controls were genotyped using the TaqmanTM platform. Odds Ratios (OR) and 95% confidence intervals (CI) for the association of the variants with the risk of lymphoma were calculated using unconditional logistic regression analysis, under the log additive inheritance model. Results: Family history of cancer was reported by 421 subjects (196 controls and 225 cases, p-value=0.001). Among those, 41 had an hematological origin. The two SNP genotyped in IL8RB gene were associated to an increase in risk of lymphoma for every extra variant allele (IL8RB +1235C&gt;T OR=1.68, 95%CI=1.25–2.27 and IL8RB -1010A&gt;G OR=1.59, 95%CI=1.17–2.17). The OR associated to an additional variant allele of Ggh IVS7-3001 polymorphism was 1.82 (95%CI=1.06–3.14). IL-1082 A&gt;G was observed to decrease the risk of lymphoma (OR=0.72, 95%CI=0.54–0.96).Restricting the analysis to those with a familial cancer of hematological origin under a log-additive inheritance model, a statistical increase in the risk was found for every extra variant allele MTHFR +429A&gt;C in the genotype (OR=21.52, 95%CI=2.42–191.08), whereas presenting at least one variant allele of IL10 -1082 A&gt;G decreased the risk of lymphoma (OR=0.05, 95%CI=0.01–0.38). In order to evaluate the association between SNPs and lymphoma subtypes in subjects with family history of cancer, we explored the relation between all statistically significant SNPs reported above and non-Hodgkin lymphomas (NHL), Chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and Hodgkin lymphoma (HL). We observe that the association of SNPs and all lymphoma is similar after stratifying by subtypes, although these results are based on few subjects. Interestingly, those SNPs related to low risk of lymphoma, were observed to have the lowest risk among HL cases (IL10 -1082 A&gt;G OR=0.28, 95%CI=0.09– 0.82), whereas HL and MM seems to be at higher risk for those SNPs related to increased risk of lymphoma (IL8RB+1235 OR=2.29, 95%CI=1.29–4.05 and IL8RB-1010 OR=2.45, 95%CI=1.33–4.51 for MM and Ggh IVS7-3001 OR=5.47, 95%CI=1.33–22.52 for HL). Conclusions: These results suggest a potential role of IL8RB, GGH IVS7 and IL10 SNPs in the risk of lymphoid neoplasms among subjects with family history of cancer. HL and MM seem to be those entities in which these associations appear to be stronger, although the number of cases included is small.


Author(s):  
Manal A. Fadl ◽  
Sahar S. Noor Algalil

IL-1β was known to cause an inflammation in heart tissue leading to progressive loss of contractile tissues. The aim of this study was to evaluate “for the first time” the relationship between IL-1β polymorphism (rs1143634) and the risk of heart diseases (HDs) in Sudanese patients. Methods: Fifty patients with HD and 65 healthy controls were enrolled in this cross-sectional study. The IL-1β (rs1143634) polymorphism was detected by PCR-RFLP using TaqI restriction enzyme. Results: About 82% of the HD cases were aged >40 years. No gender difference was reported between the two groups (P = 0.28). 24% of the cases had a previous history of heart attack. Family history of HD was associated with a six-fold increased risk of HD. The analysis provides evidence that the mutant genotype (CT + TT) of the IL1β polymorphism is significantly associated with HD, with up to four-fold increased risk of the disease (P = 0.015, OR = 3.8). The mutant allele T was significantly higher in HD patients as compared to the controls (P = 0.023). The frequency of the CT genotype among patient who have family history, previous attack of HD, hypertension, and diabetes was 79%, 33%, 81%, and 90% respectively. Conclusion: The IL1β (rs1143634) polymorphism was associated with the increased risk of HD in our samples. The carriage of the mutant allele among those who have family history of HD, previous attack, hypertension, and diabetes might be a predictive factor for the onset of clinical manifestation of HD in Sudanese patients. Key words: heart diseases’ risk factors, gene polymorphisms, Interleukin (IL)-1 β


Author(s):  
Alexander L. R. Grewcock ◽  
Karlijn E. P. E. Hermans ◽  
Matty P. Weijenberg ◽  
Piet A. Brandt ◽  
Caroline Loef ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document